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DNA fragmentation induced by the antimitotic drug estramustine in
malignant rat glioma but not in normal brain - suggesting an apoptotic
cell death
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Summary Estramustine, a combination of 17p-oestradiol and nor-nitrogen mustard, has been shown to be
metabolised and to induce specific antiproliferative effects in malignant glioma, including arrest ofglioma cells
in the G2/M phase of the cell cycle, damage to cell membranes and DNA and induction of free oxygen
radicals. To evaluate further the effects of estramustine, an in vivo rat glioma model using inbred BD-IX rats
and the BT4C cell line was set up. In order to detect cells with fragmented DNA, tumour and brain specimens
were, following fixation for histological examination, processed for in situ end labelling (ISEL) with biotin-
labelled nucleotides. Fresh tissue fragments were also used for DNA integrity analysis on agarose gels. It was
demonstrated that estramustine induced clusters of ISEL-positive cells and a pronounced typical fragmenta-
tion of DNA 0.5-8 h after treatment. In tumours examined 24 or 94 h after estramustine treatment, and in
untreated tumours, only occasional single ISEL-positive cells were scattered in the tumour. DNA from normal
brain tissue did not display any visible sign offragmentation. These changes are indicative ofprogrammed cell
death induced by estramustine in glioma cells but not in normal brain tissue. Further studies are, however,
needed to establish in detail the mechanisms of cell death following treatment with the antimitotic drug
estramustine.
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Estramustine (EaM), a fusion molecule between 17p-oestra-
diol and nor-nitrogen mustard used in the treatment of pro-
static carcinoma, has been proposed to be of interest in the
management of malignant glioma. EaM has been shown to
exert dose-dependent antiproliferative effects in glioma cells
in vitro (von Schoultz et al., 1988; Piepmeier et al., 1993) and
in vivo (Bergenheim et al., 1993a, 1994). The mechanism of
action involves the microtubule system (Hartley-Asp, 1984;
Steams, 1988; Bjermer et al., 1988; Dahllof et al., 1993) with
arrest ofglioma cells in the G2/M phase ofthe cell cycle (von
Schoultz et al., 1988). The activity seems to be independent
of the hormone and alkylating moiety of EaM (Murphy et
al., 1984; Tew and Stems, 1987). However, other targets have
also been suggested to be of importance in explaining the
cytotoxicity, such as effects on cell membrane-coupled events
(Henriksson et al., 1990; Engstrom et al., 1991; Sandstrom et
al., 1994) and DNA (von Schoultz, 1991; Piepmeier et al.,
1993), while others emphasise that non-DNA targets such as
nuclear protein matrix are of importance (Tew et al., 1983;
Hartley-Asp and Kruse, 1986; Pienta and Lehr, 1993). There-
fore, we now find it of interest to report that EaM induces
signs of a rapid and transient apoptotic cell death in malig-
nant rat glioma cells but not in the normal brain tissue of
rats.
Materials and methods
Animals
A rat glioma model using inbred BD- IX rats and the BT4C
glioma cell line was set up (Bergenheim et al., 1994). The
malignant glioma cells were grown as a monolayer for 1
week before implantation. Cells growing in log phase were
harvested and trypsinised before being spun down and
diluted in MEM supplemented with 5% BD IX rat serum to
give 20 000cells 5Sl-'. BD IX rats, 8-14 weeks old, were
anaesthetised by i.p. administration of 1.8 ml kg-' of a 1:1
mixture of Hypnorm (fluanisonum 1Omgml-' and fentany-
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lum 0.2 mgml-') and Dormicum (midazolam 5 mg ml-').
Twenty-thousand viable cells in 5gll were transplanted under
stereotactic conditions, 3.5 mm to the right of bregma at
4.5 mm depth, in the caudate nucleus. A microsyringe was
used (22S Ga needle; Unimetrics, Shorewood, IL, USA),
allowing at least 5 min for injection and withdrawal of the
needle to prevent cellular reflux and extracerebral spread of
tumour cells. The drill hole was closed with bone wax. To
ensure cell viability the cell suspension was kept on ice during
the implantation procedure and the viability of the cell
suspension was continuously controlled by staining with
trypan blue. After implantation the rats were fed ad
libitum.
Estramustine treatment
Estramustine EaM (Kabi Pharmacia, Helsingborg, Sweden)
was dissolved in a vehicle of 20 g% ethanol and then mixed
with 78 g% castor oil with 2 g of Tween 80 to give the
concentration 10mgmlhl (Eklov et al., 1992). EaM was
given intraperitoneally, 20mgkg-' as a single injection at
day 24 after implantation. At that time the tumours have an
estimated volume of 160 mm3 and do not contain necrotic
areas (Bergenheim et al., 1994). The rats were divided into
nine subgroups containing 3-6 animals in each group. At
0.5, 1, 2, 4, 8, 24 and 96 h after treatment with EaM the
animals were killed and the tissues were handled as described
below. Two control groups were used: one received no treat-
ment and one group was treated with the vehicle alone. The
brains were immediately, after decapitation, taken out and
the tumours were carefully dissected out under the micro-
scope. Normal and tumour tissues were immediately treated
as described below.
In situ end labelling (ISEL)
Several pieces of tumour tissue and non-tumour-containing
brain tissue from each animal were fixed and embedded in
paraffin, and sections 3-4gm thick were made according to
routine histology procedures. In situ detection of apoptotic
cells was visualised as follows according to the protocol by
Wijsman et al. (1993). After deparaffinisation and rehydra-Estramustine and apoptois in glioma
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tion, the sections were heated twice in SSC (sodium chloride
17.5 g, sodium citrate 8.8 g I1 water, pH 7.0; Merck Darm-
stadt, Germany) at 80°C for 20 min and subsequently washed
thoroughly in distilled water. To enable enzymatic incorpora-
tion of nucleotides, the sections were digested in 0.5% pepsin
in hydrochloric acid (pH 2) for 15 min with gentle shaking in
a 37°C water bath. The digestion was stopped by washing
several times in tap water and then washed in buffer for
5 min. After drying, the sections were incubated for 1 h at
15°C with buffer containing 0.01 mM dATP, dGTP, dCTP
and 0.01 mM biotin dUTP (Boehringer Mannheim, Mann-
heim, Germany) along with 4 U ml-' DNA polymerase 1
(Sigma, USA). Endogenous peroxidase was blocked for
5 min in PBS with 0.1% hydrogen peroxide, and the sections
were then washed twice for 5 min in PBS (0.1% hydrogen
peroxide). The sections were then incubated with avidin dis-
solved in PBS with 1% BSA (bovine serum albumin) and
0.5% Tween 20 (Boehringer Mannheim, Mannheim, Ger-
many) for 30 min at room temperature before developing
with diaminobenzidine. In negative controls, DNA poly-
merase was excluded from the nucleotide polymerase mix.
Normal rat prostate, 3 days after castration, was used as a
positive control. At that time a significant number of the
epithelial cells display characteristic features of apoptotic
cells (Dive and Wyllie, 1993). The number of ISEL-positive
cells was quantified in the light microscope expressed as cells
per surface area (Table I). Five randomly chosen areas
(5 x 10-3 cm2) in each section were counted. Sections were
also processed for routine staining with haematoxylin and
eosin.
Analysis ofDNA integrity
The analysis of DNA integrity has recently been described in
detail (Tounekti et al., 1993). Briefly, whole tissue was frozen
in liquid nitrogen and ground with a homogeniser. Tissue
fragments were suspended in digestion buffer (100 mM
sodium chloride, 10 mM Tris-HCl pH 8, 25 mM EDTA
pH 8, 0.5% sodium dodecyl sulphate and 0.1 mgml-' pro-
teinase K) and incubated at 50°C for 12 h and each sample
was treated with DNAse free RNAse (0.5 mgml-') for 1 h.
The samples were heated to 70°C. Loading buffer (0.25%
Orange G, 30 mM EDTA, 15% Ficoll) was added to each
sample at a 1:2 (v/v) ratio before loading into the 1.5%
agarose gel containing 0.Ifg ml-' ethidium bromide. Elec-
trophoresis was carried out in 0.1 M TBE (0.045M Tris-
borate, 0.001 M EDTA) at 21 V for 14-16h on 1.5%
agarose gels and viewed by transillumination with UV light
and photographed. 1 HindlII standard was used as molecular
size standard. All chemicals were from Sigma.
Results
Histological examination of the untreated BT4C tumour dis-
played a polymorphic and dense cellular appearance with
features of a gliosarcoma. Mitoses were frequent, and abnor-
mal mitotic figures were also found. The growth behaviour
was invasive with a clear tendency for perivascular growth
with nests of tumour cells developing in the normal brain.
Table I Quantitative analysis of ISEL (in situ end labelling)-positive
cells following estramustine treatment analysed at various time
intervals
Number of ISEL-positive cells (5 x 10-' cm2)
Time point (h) Mean ± s.e.m. (range)
O 0 (0-0)
0.5 47 ± 7 (30-60)
1 197 ± 17 (160-230)
2 231 ± 25 (200-264)
4 523 ± 37 (410-600)
8 453 ± 33 (400-490)
24 3± 1 (2-4)
96 0 (0-0)
No signs of inflammatory cells or necrosis were seen within
the tumour. At the border of the tumour adjacent to normal
tissue mononuclear inflammatory cells were occasionally
seen. In order to detect apoptotic cells with fragmented
DNA, tissue sections were processed for in situ end labelling
(ISEL) with biotin-labelled nucleotides. In untreated control
tumours occasional single ISEL-positive cells with morpho-
logically fragmented nuclei were seen scattered in the tumour.
At 0.5, 1, 2, 4, or 8 h after estramustine treatment clusters of
ISEL-positive cells were observed in the tumours (Figure 1).
The tumour tissue between these clusters contained only a
few labelled cells. The cell clusters varied in size and some
contained only a few whereas others contained up to 100
labelled cells. Several of the labelled cells had a fragmented
b
c
Figure 1 In situ end-labelled (ISEL) sections from malignant rat
glioma 4 h after estramustine administration to the animals: (a)
400 x magnification, (b) 800 x magnification and (c) non-treated
tumour tissue. Note the heavily ISEL-labelled cluster of tumour
cells. The normal brain from the same animal and the non-
treated tumour tissue were almost without detectable ISEL
cells.
718nucleus suggesting that they were apoptotic. We could not
detect any clear-cut signs offocal tissue necrosis. The number
of ISEL-positive cells and number of clusters increased and
reached peak values 4-8 h following estramustine treatment.
At 24h only a very few positive cells were seen (Table I).
Ninety-four hours after estramustine treatment clusters of
ISEL-positive cells were not observed and tumour mor-
phology seemed similar to non-treated controls.
Estramustine caused a typical pronounced fragmentation
of DNA in the intracranially situated glioma tumour tissue
visible 30 min following the single injection as visualised in
the gel analysis (Figure 2). A similar pattern was seen 1, 2, 4
or 8 h after the EaM delivery to the animals, whereas there
was no sign of DNA ladder 24 or 96 h later. DNA from the
normal brain tissue and untreated tumours did not display
any visible sign of fragmentation at all.
Discussion
In the present study, morphological and molecular observa-
tions for the first time suggest that estramustine (EaM)
induces signs of apoptotic cell death in malignant glioma
cells but not in non-tumour-containing brain tissue. The
degradation of genomic DNA into low molecular weight
DNA (<1000 bp) is considered as a hallmark of apoptosis
(see, for example, Dive and Wyllie, 1993; Isaacs, 1994). The
electrophoretic DNA analysis demonstrated a marked tran-
sient DNA degradation in the glioma tissue from EaM-
treated rats in contrast with that from non-treated animals
and in normal brain tissue from both treated and non-treated
animals. The in situ end labelling was used to facilitate and
enhance the accuracy of detecting apoptotic cells in the tis-
sues (Wijsman et al., 1993) using the fact that the 3'-hydroxyl
a b
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ends of the terminal deoxynucleotides in the double-stranded
DNA fragments produced during programmed cell death can
be labelled with biotinylated deoxynucleotides. Cells under-
going programmed cell death incorporate biotinylated
nucleotides into their nuclear DNA and can therefore be
identified (Gaurieli et al., 1993; Gorcyzca et al., 1993; Wijs-
man et al., 1993), however necrotic cells are also stained.
It can thus, of course, be speculated whether the observed
clusters ofcells with fragmented DNA is caused by apoptotic
or necrotic cell death. However, the demonstration of ISEL-
positive cells with fragmented nuclei suggests that at least
some of the cells in the treated tumours die of apoptosis.
Moreover, the pattern of DNA degradation with stereotypic
nucleosomal-sized fragment is characteristic of apoptotic cell
death. The response was also time dependent and disap-
peared without signs of inflammatory reaction or other signs
of necrosis. The rapid onset, i.e. detected within 30 min, may
suggest that the induction of apoptosis by EaM is a late
event in the signal pathway or that the machinery of pro-
grammed death in this particular glioma is already in some
way turned on and only needs to be triggered to be enhanced
by EaM. However, this must be further studied before any
final conclusions can be drawn.
It is of interest to recall earlier studies with EaM which
have shown effects that, in the light of current knowledge,
can be considered features of the process leading to apop-
tosis: membrane-coupled events with early influence on ion
fluxes (Engstrom et al., 1991; Sandstr6m et al., 1994) and
formation of bleb-like projections observed in glioma cells
(von Schoultz et al., 1990; Engstrom et al., 1991). Bleb
formation has been correlated with loss of cell viability
(Noseda et al., 1989) and may be related to lipid peroxida-
tion via free oxygen radicals (Noronha-Dutra et al., 1988).
Fragmentation of DNA and disturbed DNA synthesis have
c d
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Figure 2 DNA integrity analysis with agarose gel electrophoresis according to the description in Materials and methods. Samples
of normal brain tissue and estramustine-treated and non-treated control tumours marked at various time intervals were analysed
after (0.5, 1, 2, 4, 8, 24 and 96 h) EaM delivery. Note the clearly visible DNA ladder in the EaM-treated brain tumour specimens.
(a) Lanes 1-6, 0.5 h treatment with EaM (odd numbers = normal tissue, even numbers = tumour tissue); lanes 7-12 1 h treatment
with EaM; lanes 13-18, 2 h treatment with EaM; lane 19, A HindlII standard. The arrow shows 2.3 and 2.0 kb fragments; the
double arrow shows the 0.5 kb fragment. (b) Lanes 1-6, 4 h treatment with EaM (odd numbers = normal tissue, even numbers
= tumour tissue) lanes 7-10, 8 h treatment with EaM; lanes 11-16, 24 h treatment with EaM; lanes 17-20, control, non-treated
tumour tissue; lane 21, 1 HindIII standard. The arrow shows 12.3 and 2.0 kb fragments; the double arrow shows the 0.5 kb
fragment. (c) Lanes 1-6, 96 h treatment with EaM (odd numbers = normal tissue, even numbers = tumour tissue); lane 7, A
HindlII standard. The arrow shows 2.3 and 2.0 kb fragments; the double arrow shows the 0.5 kb fragment. (d) Lanes 1-6,
treatment with only the vehicle solution (odd numbers = normal tissue, even numbers = tumour tissue); lane 7, A HindlII standard.
The arrow shows 2.3 and 2.0 kb fragments; the double arrow shows the 0.5 kb fragment.
1.-
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also been observed in glioma cells after exposure to EaM
(von Schoultz et al., 1991; Piepmeier et al., 1993). The obser-
vation of a rapid induction of free oxygen radicals following
EaM treatment (Henriksson et al., 1990) must also be
emphasised since free radicals are proposed to be involved in
the late steps in the pathways leading to apoptosis (Hocken-
bery et al., 1993).
In conclusion, the antimitotic drug estramustine induced
clearly visible early damage ofDNA in tumour tissue but not
in brain tissue from the same animals. This difference in
reaction between glioma and brain tissue is of special interest
and must be further analysed. EaM has previously been
shown to penetrate the blood-tumour barrier and to accumu-
late both in human brain tumours (Bergenheim et al., 1993b)
and in brain tumours in rats (Bergenheim et al., 1994). In
this respect it is also of interest to recall the recently pub-
lished results that EaM affects microtubule integrity and
displays cytotoxic action only in glioma cells but not in
astrocytes (Yoshida et al., 1994). Although there is strong
evidence that the mechanism of fragmentation of DNA is
most likely programmed cell death, further studies are needed
to evaluate the changes within the tumour cells that result in
cell death. However, the results support the observations
(von Schoultz et al., 1991; Piepmeier, 1993) that the anti-
mitotic drug estramustine can specifically induce alteration in
DNA integrity. This is still, however, in agreement with the
earlier proposed main mechanism of EaM's antimitotic
action being interaction with the microtubule system and
nuclear matrix (Tew, 1983; Murphy et al., 1984; Tew and
Steams, 1987; Pienta and Lehr, 1993). The cell death induced
by EaM may primarily be a membrane/cytoskeletal-triggered
apoptotic cell death rather than a direct chemical interaction
with the DNA.
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